Diagnosis value of the detection of CYFRA21-1 in non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 13, Issue 12, 2010, Pages 1118-1121

  Gu, Jundong ^a   Wang, Xinzhuo ^a   Zhao, Hui ^a   Zhu, Siwei ^a   Wen, Yanjun ^b   Xu, Hongrui ^a   Li, L I ^a   Chen, Jun ^b   Zhou, Qinghua ^b  

^a TIANJIN PEOPLE'S HOSPITAL   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Antigen CYFRA21 1; Diagnosis; Lung neoplasms; ROC curve

Indexed keywords

CYTOKERATIN 19 FRAGMENT;

AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER STAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KERATIN-19; MALE; MIDDLE AGED;

EID: 78650924640     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2010.12.07     Document Type: Article

References (17)

1. Jones FA, Takai D. The role of DNA methylation in mammalian epigenetics. Science, 2001, 293(5532): 1068-1070.
2. Bird A. DNA methylation de novo. Science, 1999, 286(5448): 2287-2288.
3. Sun NC, Edgington TD, Carpentier CL, et al. Immunohistochemical localization of carcinoembryonic antigen (CEA), CEA-S, and nonspecific cross-reacting antigen (NCA) in carcinomas of lung. Cancer, 1983, 52(9): 1632-1641.
4. Akoun GM, Scarna HM, Milleron BJ, et al. Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer. Chest, 1985, 87(1): 39-43.
5. Gasser RW, Herold M, Müller-Holzner E, et al. Neuron-specific enolase as a tumor marker in small cell bronchial carcinoma. Dtsch Med Wochenschr, 1988, 113(44): 1708-1713.
6. Mino N, Iio A, Hamamoto K. Availability of tumor-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs. Cancer, 1988, 62(4): 730-734.
7. Pujol JL, Grenier J, Daurès JP, et al. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res, 1993, 53(1): 61-66.
8. Ginsberg MS. Epidemiology of lung cancer. Semin Roentgenol, 2005, 40(2): 83-89.
9. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346(2): 92-98. (Pubitemid 34438899)
10. Mattson ME, Pollack ES, Cullen JW. What are the odds that smoking will kill you? Am J Public Health, 1987, 77(4): 425-431.
11. Bastarrika G, Garcia-Velloso MJ, Lozano MD, et al. Early lung cancer detection using spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med, 2005, 171(12): 1378-1383.
12. Twombly R. Lung cancer screening debate continues despite international CT study results. J Natl Cancer Inst, 2007, 99(3): 190-195.
13. Marshall E. Medicine. A bruising battle over lung scans. Science, 2008, 320(5876): 600-603.
14. Stieher P, Hasholzner U, Bcdermuller H, et al. CYFRA21-1. A new maker in lung cancer. Cancer, 1993, 72(3): 707-713.
15. Broers J, Ramaekers FC, Rot MK, et al. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res, 1988, 48(11): 3221-3229.
16. Swets JA. ROC analysis applied to the evaluation of medical imaging techniques. Invest Radiol, 1979, 14(2): 109-121.
17. Pujol JL, Grenier J, Daurès JP, et al. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res, 1993, 53(1): 61-66.